Pesquisar
Glaukos Corp
GKOSAdicionar à lista de desejos
137.230USD
+0.870+0.64%
Fechamento 05/13, 16:00（ET）Cotações atrasadas em 15 min
7.89BValor de mercado
PerdaP/L TTM
Mais detalhes de Glaukos Corp Empresa
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Informações de Glaukos Corp
Código da empresaGKOS
Nome da EmpresaGlaukos Corp
Data de listagemJun 25, 2015
CEOBurns (Thomas William)
Número de funcionários995
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
Endereço1 Glaukos Way
CidadeALISO VIEJO
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal92656
Telefone19493679600
Sitehttps://www.glaukos.com
Código da empresaGKOS
Data de listagemJun 25, 2015
CEOBurns (Thomas William)
Executivos da empresa Glaukos Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
+4.98%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
70.09K
-0.25%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
57.22K
-0.53%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
50.58K
-4.49%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
49.69K
+1.65%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
36.72K
-0.51%
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
+4.98%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
70.09K
-0.25%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
57.22K
-0.53%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
50.58K
-4.49%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
49.69K
+1.65%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
36.72K
-0.51%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Glaucoma
421.07M
82.98%
Corneal Health
86.37M
17.02%
Por RegiãoUSD
Nome
Receita
Proporção
United States
375.04M
73.91%
International
132.40M
26.09%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Glaucoma
421.07M
82.98%
Corneal Health
86.37M
17.02%
Distribuição de ações
Atualizado em: seg, 11 de mai
Atualizado em: seg, 11 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
13.75%
PRIMECAP Management Company
5.74%
Vanguard Portfolio Management, LLC
5.46%
Janus Henderson Investors
5.14%
Vanguard Capital Management, LLC
4.27%
Outro
65.64%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
13.75%
PRIMECAP Management Company
5.74%
Vanguard Portfolio Management, LLC
5.46%
Janus Henderson Investors
5.14%
Vanguard Capital Management, LLC
4.27%
Outro
65.64%
Tipos de investidores
Investidores
Proporção
Investment Advisor
50.27%
Investment Advisor/Hedge Fund
31.21%
Hedge Fund
11.62%
Individual Investor
3.59%
Research Firm
1.93%
Pension Fund
1.52%
Sovereign Wealth Fund
0.91%
Bank and Trust
0.79%
Venture Capital
0.50%
Participação acionária institucional
Atualizado em: dom, 5 de abr
Atualizado em: dom, 5 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
702
59.35M
101.04%
-2.78M
2025Q4
679
58.33M
101.56%
-6.75M
2025Q3
653
61.34M
106.80%
+235.97K
2025Q2
638
61.06M
106.48%
+15.37K
2025Q1
643
60.20M
105.40%
-1.30M
2024Q4
610
59.75M
105.65%
+533.86K
2024Q3
567
57.47M
104.31%
-894.95K
2024Q2
545
56.86M
103.79%
-713.22K
2024Q1
509
54.47M
110.12%
-1.91M
2023Q4
480
53.71M
109.34%
-1.79M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
8.07M
13.9%
+267.99K
+3.43%
Dec 31, 2025
PRIMECAP Management Company
3.38M
5.81%
+1.12M
+49.83%
Dec 31, 2025
Janus Henderson Investors
3.02M
5.2%
+1.95M
+183.40%
Dec 31, 2025
State Street Investment Management (US)
2.12M
3.65%
+18.04K
+0.86%
Dec 31, 2025
Burns (Thomas William)
1.62M
2.78%
+11.71K
+0.73%
Mar 25, 2026
AllianceBernstein L.P.
1.64M
2.83%
-90.03K
-5.19%
Dec 31, 2025
Millennium Management LLC
1.61M
2.77%
+696.29K
+76.23%
Dec 31, 2025
Geode Capital Management, L.L.C.
1.32M
2.27%
+1.56K
+0.12%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco S&P SmallCap Health Care ETF
3.09%
Alger Weatherbie Enduring Growth ETF
2.07%
State Street SPDR S&P Health Care Equipment ETF
1.79%
ROBO Global Healthcare Technology & Innovation ETF
1.4%
State Street SPDR S&P 600 Small Cap Growth ETF
0.69%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.65%
iShares S&P Small-Cap 600 Growth ETF
0.64%
iShares U.S. Medical Devices ETF
0.6%
OneAscent Enhanced Small and Mid Cap ETF
0.53%
State Street SPDR S&P SmallCap 600 ESG ETF
0.51%
Ver Mais
Invesco S&P SmallCap Health Care ETF
Proporção3.09%
Alger Weatherbie Enduring Growth ETF
Proporção2.07%
State Street SPDR S&P Health Care Equipment ETF
Proporção1.79%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.4%
State Street SPDR S&P 600 Small Cap Growth ETF
Proporção0.69%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proporção0.65%
iShares S&P Small-Cap 600 Growth ETF
Proporção0.64%
iShares U.S. Medical Devices ETF
Proporção0.6%
OneAscent Enhanced Small and Mid Cap ETF
Proporção0.53%
State Street SPDR S&P SmallCap 600 ESG ETF
Proporção0.51%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
